Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xiaoyu Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9888-5836; OpenAlex author ID A5100455492. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 7

  1. Irreversible electroporation combined with PD-L1/IL-6 dual blockade promotes anti-tumor immunity via cDC2/CD4+T cell axis in MHC-I deficient pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217620↗
  2. HNRNPC regulates RhoA to induce DNA damage repair and cancer-associated fibroblast activation causing radiation resistance in pancreatic cancer. Co-author DOI 10.1111/jcmm.17254↗
  3. hnRNPC Promotes Malignancy in Pancreatic Cancer through Stabilization of IQGAP3. Co-author DOI 10.1155/2022/6319685↗
  4. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2019.02.010↗
  5. Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer. Co-author DOI 10.7150/jca.23989↗
  6. Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up c… First author DOI 10.2147/ott.s116136↗
  7. Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1097/md.0000000000003098↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhongmin Wang · 2 shared papers, 2022–2025 · strength 0.37
  2. Nannan Yang · 2 shared papers, 2022 · strength 0.34
  3. Guofeng Zhou · 3 shared papers, 2016–2018 · strength 0.21
  4. Wenguo Cui · 1 shared paper, 2025 · strength 0.21
  5. Zhuozhuo Wu · 1 shared paper, 2025 · strength 0.21
  6. Chenlei Wen · 1 shared paper, 2025 · strength 0.21
  7. Zhongmin Wang · 1 shared paper, 2022 · strength 0.19
  8. Ning Xia · 1 shared paper, 2022 · strength 0.16
  9. Wei Huang · 1 shared paper, 2022 · strength 0.16
  10. Xiaolin Wang · 2 shared papers, 2017–2019 · strength 0.15
  11. Yuan Ji · 1 shared paper, 2019 · strength 0.08
  12. Tao Wei · 1 shared paper, 2019 · strength 0.08
  13. Yi Chen · 1 shared paper, 2018 · strength 0.07
  14. Xiaolin Wang · 1 shared paper, 2018 · strength 0.07
  15. Wenhui Lou · 1 shared paper, 2018 · strength 0.07
  16. Junhao Li · 1 shared paper, 2018 · strength 0.07
  17. Changyu Li · 1 shared paper, 2016 · strength 0.07
  18. Xiaolin Wang · 1 shared paper, 2016 · strength 0.07
  19. Dayong Jin · 1 shared paper, 2017 · strength 0.07
  20. Deliang Fu · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.